Tau Oligomers in Sera of Patients with Alzheimer's Disease and Aged Controls
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články, práce podpořená grantem, Research Support, N.I.H., Extramural
Grantová podpora
R01 AG054025
NIA NIH HHS - United States
R01 NS094557
NINDS NIH HHS - United States
PubMed
28453485
DOI
10.3233/jad-170048
PII: JAD170048
Knihovny.cz E-zdroje
- Klíčová slova
- Alzheimer’s disease, oligomers, serum, tau protein,
- MeSH
- Alzheimerova nemoc krev mozkomíšní mok komplikace MeSH
- amyloidní beta-protein krev mozkomíšní mok MeSH
- ELISA MeSH
- kognitivní dysfunkce krev etiologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- peptidové fragmenty krev MeSH
- proteiny tau krev mozkomíšní mok chemie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- stárnutí krev MeSH
- záznam o duševním stavu MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
- Názvy látek
- amyloidní beta-protein MeSH
- peptidové fragmenty MeSH
- proteiny tau MeSH
Although tau protein was long regarded as an intracellular protein with several functions inside the cell, new evidence has shown tau secretion into the extracellular space. The active secretion of tau could be a physiological response of neurons to increased intracellular amounts of tau during the progression of tau pathology. We looked for potential differences in the serum levels of toxic tau oligomers in regards to cognitive impairment of subjects. We detected tau oligomers in the serum of Alzheimer's disease (AD) patients, but they were also present to some extent in the serum of healthy older subjects where the levels positively correlated with aging (Spearman r = 0.26, p = 0.016). On the contrary, we found lower levels of tau oligomers in the serum of mild cognitive impairment (MCI) (p = 0.033) and MCI-AD (p = 0.006) patients. These results could suggest that clearance of extracellular tau proteins takes place, in part, in the periphery. In the case of MCI patients, the lower levels of tau oligomers could be the result of impaired clearance of tau protein from interstitium to blood and consequent accumulation of tau aggregates in the brain.
3rd Faculty of Medicine Charles University Prague Czech Republic
Mitchell Center for Neurodegenerative Diseases University of Texas Medical Branch Galveston TX USA
Citace poskytuje Crossref.org